Bg pattern

ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

0.0 (0)
Doctor

Bulat Garipov

General medicine 15 years exp.

Dr. Bulat Garipov is a radiologist with more than 15 years of experience, specializing in magnetic resonance imaging (MRI). Throughout his professional career, he has worked in leading diagnostic imaging centers, both in on-site practice and teleradiology, which has allowed him to develop a broad and versatile approach to radiology.

Over the years, he has gained solid experience in interpreting MRI studies in various areas, including:

  •  Neuroimaging
  •  Musculoskeletal system (MSK)
  •  Angiography
  •  Abdomen and pelvis
  •  Soft tissues

Additionally, Dr. Garipov is open to new collaboration opportunities in radiology and teleradiology projects. He offers his expertise in MRI, providing both first and second readings of studies, as well as advanced image interpretation, ensuring accurate and high-quality diagnostics.

You could consult Dr. Bulat Garipov in cases where accurate interpretation of MRI studies or a second expert opinion is required. His expertise is especially valuable in cases of suspected neurological conditions, back and joint pain, vascular disorders, as well as in the diagnosis of abdominal and pelvic diseases. The doctor also provides support in complex or unclear clinical situations, including the review of previously performed studies, which helps improve diagnostic accuracy and determine the optimal treatment strategy. A teleradiology format is available, allowing you to receive a professional opinion remotely.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

EndolucinBeta 40 GBq/ml Radiopharmaceutical Precursor in Solution

Lutetium Chloride (177Lu)

This medicinal product is subject to additional monitoring. This will allow for the quick identification of new safety information. You can help by reporting any side effects you may experience. The last section of section 4 will provide information on how to report side effects.

Read all of this leaflet carefully before you start receiving the medicinal product combined with EndolucinBeta, because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your nuclear medicine doctor who will be supervising the procedure.
  • If you experience side effects, consult your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the Package Leaflet

  1. What is EndolucinBeta and what is it used for
  2. What you need to know before you are given the radiolabelled medicinal product with EndolucinBeta
  3. How to use the radiolabelled medicinal product with EndolucinBeta
  4. Possible side effects
  1. Storage of EndolucinBeta
  2. Package Contents and Further Information

1. What is EndolucinBeta and what is it used for

EndolucinBeta is not the final medicinal product and must not be used on its own. It must be used in combination with another medicinal product (carrier medicinal product).

EndolucinBeta is a type of product known as a radiopharmaceutical precursor. It contains the active substance lutetium chloride (177Lu) which emits beta radiation, allowing for a localized radiation effect. This radiation is used to treat certain diseases.

EndolucinBeta must be combined with a carrier medicinal product in a process known as radiolabelling before administration. The carrier medicinal product then takes EndolucinBeta to the site in the body where the disease is located.

These carrier medicinal products have been specifically developed for use with lutetium chloride (177Lu) and may be substances designed to recognize a specific type of cell in the body.

Administration of radiolabelled medicinal products with EndolucinBeta involves exposure to radioactivity. Your doctor and nuclear medicine doctor have considered that the clinical benefit you will receive from the procedure with the radiopharmaceutical outweighs the risks of radiation.

Refer to the package leaflet of the medicinal product that will be radiolabelled with EndolucinBeta.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you are given the radiolabelled medicinal product with EndolucinBeta

The radiolabelled medicinal product with EndolucinBeta must not be used

  • if you are allergic to lutetium chloride (177Lu) or any of the other ingredients of this medicinal product (listed in section 6).
  • if you are pregnant or think you may be pregnant.

Refer to the package leaflet of the medicinal product that will be radiolabelled with EndolucinBeta for more information.

Warnings and Precautions

EndolucinBeta must not be administered directly to patients.

Be particularly careful with the radiolabelled medicinal product with EndolucinBeta:

  • if you have kidney problems or bone marrow disease.

Treatment with lutetium (177Lu) labelled ligands may cause the following side effects:

  • Reduced red blood cell count (anaemia).
  • Reduced platelet count in the blood (thrombocytopenia), which are important for stopping bleeding.
  • Reduced white blood cell count (leucopenia, lymphopenia or neutropenia), which are important for protecting the body against infections.

Most of these events are mild and transient. In some patients, a reduction in the number of all three types of blood cells (red blood cells, platelets and white blood cells - pancytopenia) has been described, which may require interruption of treatment.

Because lutetium (177Lu) may sometimes affect your blood cells, your doctor will perform blood tests before starting treatment and at regular intervals during treatment. Talk to your doctor if you experience shortness of breath, bruising, nosebleeds, bleeding gums or if you develop a fever.

During peptide receptor radionuclide therapy of neuroendocrine tumours, the kidneys excrete radiolabelled somatostatin analogues. Therefore, your doctor will perform a blood test to measure kidney function before starting treatment and during treatment.

Treatment with lutetium (177Lu) may cause changes in liver function. Your doctor will perform a blood test to monitor your liver function during treatment.

Radiolabelled medicinal products with lutetium (177Lu) may be administered directly into a vein through a tube called a cannula. Leaks of fluid into the surrounding tissue (extravasation) have been reported. Talk to your doctor if you experience swelling or pain in the arm.

After neuroendocrine tumours are treated with lutetium (177Lu), patients may experience symptoms associated with the release of hormones from tumour cells, known as a carcinoid crisis. Inform your doctor if you feel dizzy or weak or experience flushing or diarrhoea after treatment.

Treatment with lutetium (177Lu) may cause tumour lysis syndrome, due to the rapid destruction of tumour cells. This may cause abnormal blood test results, irregular heartbeats, kidney failure or seizures within a week after treatment. Your doctor will perform blood tests to monitor for this syndrome. Inform your doctor if you experience muscle cramps, muscle weakness, confusion or difficulty breathing.

Refer to the package leaflet of the medicinal product that will be radiolabelled with EndolucinBeta for additional warnings and precautions.

Children and Adolescents

EndolucinBeta must not be used directly in children and adolescents under 18 years of age.

Other Medicinal Products and Radiolabelled Medicinal Products with EndolucinBetaInform your nuclear medicine doctor if you are taking, have recently taken or might take

any other medicinal product, as some medicinal products may interfere with the interpretation of images.

It is not known if lutetium chloride (177Lu) can interact with other medicinal products, as specific studies have not been performed.

Pregnancy and Breast-feeding

You must inform your nuclear medicine doctor before administration of radiolabelled medicinal products with EndolucinBeta if there is any possibility that you may be pregnant, if you have a delayed period or if you are breast-feeding.

In case of doubt, it is important that you consult your nuclear medicine doctor who is supervising the procedure. If you are pregnant

Radiolabelled medicinal products with EndolucinBeta must not be administered if you are pregnant.

If you are breast-feeding

You will be asked to stop breast-feeding.

Please consult your nuclear medicine doctor when you can restart breast-feeding.

Driving and Using Machines

Your ability to drive and use machines may be affected by the medicinal product used in combination with EndolucinBeta. Please read the package leaflet of the medicinal product in question carefully.

3. How to use the Radiolabelled Medicinal Product with EndolucinBeta

There are strict rules for the use, handling and disposal of radiopharmaceuticals. Radiolabelled medicinal products with EndolucinBeta will be used in special controlled areas. This product will only be handled and administered by trained and qualified personnel who are authorized to use it safely. These people will take special care in the safe use of this product and will inform you of their actions.

The nuclear medicine doctor supervising the procedure will decide the amount of radiolabelled medicinal product with EndolucinBeta to be used in your case. This will be the minimum amount necessary to achieve the desired effect, depending on the medicinal product taken with EndolucinBeta and its intended use.

Administration of the Radiolabelled Medicinal Product with EndolucinBeta and Performance of the Procedure

EndolucinBeta must only be used in combination with another medicinal product (carrier medicinal product) that has been specifically developed and authorized for combination with lutetium chloride (177Lu).

Administration will depend on the type of carrier medicinal product. Please read the package leaflet of that medicinal product carefully.

Duration of the Procedure

Your nuclear medicine doctor will inform you about the usual duration of the procedure.

After Administration of the Radiolabelled Medicinal Product with EndolucinBeta, you should

Your nuclear medicine doctor will inform you if you need to take special precautions after administration of the radiolabelled medicinal product with EndolucinBeta. Consult your nuclear medicine doctor if you have any doubts.

If you have been given too much Radiolabelled Medicinal Product with EndolucinBeta

The nuclear medicine doctor will handle the radiolabelled medicinal product with EndolucinBeta under strictly controlled conditions, so it is very unlikely that an overdose will occur. However, in case of overdose or accidental intravenous injection of the unlabelled product, you will receive appropriate treatment that will remove the radionuclide from the body.

If you have any further questions about the use of the radiolabelled medicinal product with EndolucinBeta, consult your nuclear medicine doctor who is supervising the procedure.

.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible Side Effects

As with all medicinal products, the radiolabelled medicinal product with EndolucinBeta may cause side effects, although not everybody gets them.

Dry mouth has been reported in patients with prostate cancer who received treatment with lutetium (177Lu) and this side effect has been transient.

Very common side effects (may affect more than 1 in 10 people):

  • Reduced blood cell count (platelets, red or white blood cells)
  • Nausea
  • Vomiting

Side Effects Reported in Patients Treated for Neuroendocrine Tumours:

Very common (may affect more than 1 in 10 people):

  • Mild and temporary hair loss

Common (may affect up to 1 in 10 people):

  • Bone marrow cancer (myelodysplastic syndrome)
  • Reduced white blood cell count (neutropenia)

Uncommon (may affect up to 1 in 100 people):

  • Bone marrow cancer (acute myeloid leukaemia)

Frequency not known (cannot be estimated from the available data):

  • Carcinoid crisis
  • Tumour lysis syndrome (rapid destruction of tumour cells)
  • Reduced red blood cell, platelet and white blood cell count (pancytopenia)
  • Dry mouth

Cases of bone marrow cancer (myelodysplastic syndrome and acute myeloid leukaemia) have been reported in patients several years after treatment with peptide receptor radionuclide therapy of neuroendocrine tumours labelled with lutetium (177Lu).

After administration of the radiolabelled medicinal product with EndolucinBeta, you will release a certain amount of ionizing radiation (radioactivity) which carries a risk of cancer and genetic defects. In all cases, the radiation risk is outweighed by the potential benefits of administration of the radiolabelled medicinal product.

If you require further information, refer to the package leaflet of the specific medicinal product that will be radiolabelled.

Reporting of Side Effects

If you experience side effects, consult your nuclear medicine doctor, even if they are possible side effects not listed in this leaflet. You can also report them directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicinal product.

5. Storage of EndolucinBeta

You will not need to store this medicinal product. The medicinal product is stored under the responsibility of the specialist in suitable facilities. The storage of radiopharmaceuticals will be carried out in accordance with national regulations on radioactive materials.

The following information is intended for the specialist only.

Keep this medicinal product out of the sight and reach of children.

EndolucinBeta must not be used after the expiry date and time stated on the label after EXP.

EndolucinBeta will be stored in its original packaging which provides protection from radiation.

.

6. Package Contents and Further Information

Composition of EndolucinBeta

  • Its active substance is lutetium chloride (177Lu). 1 ml of sterile solution contains 40 GBq of lutetium chloride (177Lu) at the date and time of calibration (which corresponds to 10 micrograms of lutetium (177Lu) as lutetium chloride (177Lu)). (GBq: Gigabecquerel is the unit in which radioactivity is measured)
  • The other ingredient is hydrochloric acid solution.

Appearance of EndolucinBeta and Package Contents

EndolucinBeta is a radiopharmaceutical precursor in solution. It is presented as a clear and colourless solution in a 2 ml or 10 ml colourless glass vial of type I with a bromobutyl stopper, closed with an aluminium seal.

Each package contains 1 vial, which is placed in a lead container for shielding and packaged in a metal can and outer cardboard box.

The volume of one vial ranges from 0.075-3.75 ml of solution (which corresponds to 3-150 GBq at the date and time of calibration). The volume depends on the amount of medicinal product combined with EndolucinBeta necessary for administration by the nuclear medicine specialist.

Marketing Authorisation Holder and Manufacturer

ITM Medical Isotopes GmbH

Lichtenbergstrasse 1

D-85748 Garching

Germany

Tel: + 49-89-289 139-08

[email protected]

Date of Last Revision of this Leaflet: {Month YYYY}

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.

------------------------------------------------------------------------------------------------------------------------

This information is intended for healthcare professionals only:

The full summary of product characteristics of EndolucinBeta is included as a separate document in the product packaging, in order to provide healthcare professionals with additional scientific and practical information on the administration and use of this radiopharmaceutical.

Please refer to this summary of product characteristics.

Online doctors for ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION

Discuss questions about ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (18)
Doctor

Anastasiia Hladkykh

Psychiatry 15 years exp.

Dr Anastasiia Hladkykh is a physician-psychotherapist and psychologist with over 14 years of experience working with individuals struggling with various types of addictions and their families. She provides online consultations for adults, combining medical knowledge with deep psychological support and practical tools.

Key areas of expertise:

  • Addiction treatment: alcohol and drug dependence, gambling addiction, compulsive behaviours, codependent relationships.
  • Support for families of addicted individuals, behavioural correction within the family system, guidance for maintaining remission.
  • Mental health: depression, bipolar disorder, obsessive-compulsive disorder (OCD), anxiety disorders, phobias, PTSD, generalised anxiety, emotional trauma, and the psychological impact of loss or emigration.
  • Psychoeducation: explaining complex mental health concepts in simple language, helping patients and their families understand diagnoses and treatment steps.
Therapeutic approach:
  • Client-centred, straightforward, and empathetic – focused on practical outcomes and emotional stabilisation.
  • Prescribes medications when needed, but always aims to minimise unnecessary pharmaceutical use.
  • Certified in multiple evidence-based methods: CBT, NLP (Master Practitioner), Ericksonian hypnosis, symbol drama, art therapy, and systemic therapy.
  • Each consultation results in a clear, structured plan – patients leave knowing exactly what to do next.
Experience and background:
  • Member of the German association Gesundheitpraktikerin and the NGO “Mit dem Sonne in jedem Herzen.”
  • More than 18 publications in international peer-reviewed journals, translated into several languages.
  • Volunteer work with Ukrainian refugees and military personnel at the University Clinic of Regensburg.
0.0 (0)
Doctor

Sviatoslav Chekhun

Oncology 13 years exp.

Dr. Sviatoslav Chekhun is a medical oncologist with international clinical and research experience, specializing in modern medical oncology and a personalized approach to cancer treatment.

Currently (since 2025), he works as a Medical Oncologist at Institut Català d’Oncologia (Girona, Spain). Previously, he completed his residency in Medical Oncology and was involved in clinical research at Hospital Universitari Germans Trias i Pujol.

Dr. Chekhun has a strong academic and scientific background. He served as a lecturer in Internal Medicine at O.O. Bohomolets National Medical University and conducted research in experimental oncology at the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology.

Earlier in his career, he worked as a medical oncologist at the Kyiv City Clinical Oncological Center and contributed to regulatory evaluation of medicinal products at the State Expert Center of the Ministry of Health of Ukraine.

When to consult Dr. Chekhun:

  •  for diagnosis or clarification of a cancer diagnosis
  •  to obtain a second opinion on an existing treatment plan 
  •  when you need a personalized treatment strategy 
  •  for interpretation of test results, CT, MRI, PET-CT, and biopsies 
  •  when choosing between treatment options (chemotherapy, targeted therapy, immunotherapy) 
  •  in case of doubts about treatment strategy or disease progression 

Consultation format

Dr. Chekhun provides online consultations, where you can receive:

  •  expert second opinion 
  •  detailed case review 
  •  recommendations based on current international treatment guidelines 
  •  personalized treatment and follow-up plan 

Important:
Prescription and monitoring of medications must be carried out by your treating physician in an in-person (offline) setting. An online consultation does not replace a face-to-face visit but helps you make more informed decisions about your treatment.

Dr. Sviatoslav Chekhun combines clinical practice, research, and international experience, enabling him to provide patients with modern, evidence-based approaches in oncology.

5.0 (924)
Doctor

Alina Tsurkan

Family medicine 13 years exp.

Dr. Alina Tsurkan is a licensed family medicine physician based in Portugal, offering online consultations for adults and children. She provides professional primary care, with a focus on prevention, accurate diagnosis, and long-term management of acute and chronic conditions.

Dr. Tsurkan supports patients with a wide range of health issues, including:

  • Respiratory infections: cold, flu, bronchitis, pneumonia, and lingering coughs.
  • ENT conditions: sinusitis, tonsillitis, otitis (ear infections), sore throat, allergic rhinitis.
  • Eye conditions: allergic or infectious conjunctivitis, red eyes, irritation.
  • Digestive issues: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), constipation, bloating, nausea.
  • Urinary and reproductive health: urinary tract infections (UTIs), cystitis, prevention of recurrent infections.
  • Chronic diseases: hypertension, elevated cholesterol, weight management.
  • Neurological complaints: headaches, migraines, sleep disturbances, fatigue, general weakness.
  • Children’s health: fever, infections, digestive issues, follow-ups, vaccination guidance.

She also provides:

  • IMT medical certificates for driving licence exchange in Portugal.
  • Personalised preventive care and wellness consultations.
  • Interpretation of test results and medical reports.
  • Follow-up care and medication review.
  • Support in managing multiple coexisting conditions.
  • Remote prescription management and medical documentation.

Dr. Tsurkan’s approach is evidence-based and holistic. She works closely with each patient to develop an individualised care plan that addresses both symptoms and root causes. Her goal is to empower patients to take control of their health and maintain well-being through lifestyle adjustments, routine check-ups, and early intervention.

0.0 (0)
Doctor

Bulat Garipov

General medicine 15 years exp.

Dr. Bulat Garipov is a radiologist with more than 15 years of experience, specializing in magnetic resonance imaging (MRI). Throughout his professional career, he has worked in leading diagnostic imaging centers, both in on-site practice and teleradiology, which has allowed him to develop a broad and versatile approach to radiology.

Over the years, he has gained solid experience in interpreting MRI studies in various areas, including:

  •  Neuroimaging
  •  Musculoskeletal system (MSK)
  •  Angiography
  •  Abdomen and pelvis
  •  Soft tissues

Additionally, Dr. Garipov is open to new collaboration opportunities in radiology and teleradiology projects. He offers his expertise in MRI, providing both first and second readings of studies, as well as advanced image interpretation, ensuring accurate and high-quality diagnostics.

You could consult Dr. Bulat Garipov in cases where accurate interpretation of MRI studies or a second expert opinion is required. His expertise is especially valuable in cases of suspected neurological conditions, back and joint pain, vascular disorders, as well as in the diagnosis of abdominal and pelvic diseases. The doctor also provides support in complex or unclear clinical situations, including the review of previously performed studies, which helps improve diagnostic accuracy and determine the optimal treatment strategy. A teleradiology format is available, allowing you to receive a professional opinion remotely.

5.0 (2)
Doctor

Pedro Alvarez Guerrero

Psychiatry 8 years exp.

Dr. Alvarez Guerrero graduated in Medicine from the San Pablo CEU University in Madrid. He subsequently completed his specialization in Psychiatry in the Department of Psychiatry at Hospital Sant Joan de Deu in Manresa (Barcelona), where over the course of four years he acquired solid training in the bio-psycho-social model, developing his expertise across the different areas of mental health.

During his residency, he undertook training placements at Hospital Clínic de Barcelona, where he trained for several months in the psychiatric consultation-liaison unit. He also completed another placement at Hospital de Cruces in Bilbao, in the first-episode psychosis unit.

Throughout his professional career, Dr. Alvarez Guerrero has sought to complement his medical training with psychotherapeutic tools that allow him to address mental health disorders from a comprehensive perspective. For this reason, he specialized in Brief Strategic Psychotherapy through the Spanish Society of Psychosomatic Medicine and Psychotherapy, an approach focused on targeted and effective interventions.

With the aim of deepening his knowledge and promoting the rational use of treatments, he also completed a Master’s Degree in Psychopharmacology at the University of Valencia, which has enabled him to rigorously integrate the most up-to-date scientific evidence into the clinical management of psychopharmacological treatments.

He has also shown a particular interest in the field of legal psychiatry, completing an Official Master’s Degree in Legal, Forensic and Criminological Psychopathology at the Universitat Internacional de Catalunya. This training has allowed him to acquire the necessary competencies for the preparation of psychiatric expert reports in judicial and medico-legal contexts, thereby broadening the scope of his professional activity.

...
4

Get ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION Prescription Online

1

Fill in a 2-min form

Tell us your symptoms, history, and what medicine you're requesting.

2

Pick a doctor or let us assign

Choose a specialist or we'll match you with the next available doctor.

3

Doctor reviews your case

Usually within 30 minutes. They may ask follow-up questions via chat.

4

Collect from any pharmacy

Electronic prescription sent to your email — valid across Spain.

Frequently Asked Questions

Is a prescription required for ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION?

ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.

Who manufactures ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION?

ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION is manufactured by Itm Medical Isotopes Gmbh. Pharmacy brands and packaging may differ depending on the distributor.

Which doctors can assess the use of ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION online?

Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.

How to buy ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION in Spain?

Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.

You can buy ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.

To obtain a prescription, you can use Oladoctor:

What are the alternatives to ENDOLUCINBETA 40 GBq/mL RADIOFARMACEUTICAL PRECURSOR IN SOLUTION?

Other medicines with the same active substance () include LUTATHERA 370 MBq/mL SOLUTION FOR INFUSION, PLUVICTO 1000 MBq/mL Injectable Solution and Perfusion Solution, Xofigo 1100 kBq/ml injectable solution. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.

bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media